CL2018003114A1 - Compuesto fenólico y combinación del mismo con una benzodiazepina fusionada a 1,4-dihidropiridina para el tratamiento de afecciones del sistema nervioso central y vascular. - Google Patents

Compuesto fenólico y combinación del mismo con una benzodiazepina fusionada a 1,4-dihidropiridina para el tratamiento de afecciones del sistema nervioso central y vascular.

Info

Publication number
CL2018003114A1
CL2018003114A1 CL2018003114A CL2018003114A CL2018003114A1 CL 2018003114 A1 CL2018003114 A1 CL 2018003114A1 CL 2018003114 A CL2018003114 A CL 2018003114A CL 2018003114 A CL2018003114 A CL 2018003114A CL 2018003114 A1 CL2018003114 A1 CL 2018003114A1
Authority
CL
Chile
Prior art keywords
central
treatment
nervous system
dihydropyridine
benzodiazepine
Prior art date
Application number
CL2018003114A
Other languages
English (en)
Inventor
Figueredo Yanier Núñez
Guerra Maylin Wong
Fonseca Luis Arturo Fonseca
Sánchez Jeney Ramírez
Andreu Gilberto Lázaro Pardo
Reyes Yamila Verdecia
Rodríguez Estael Ochoa
Fernández Pedro Gilberto Bárzaga
Alfonso Nicté González
Hernández René Delgado
Navarro Claudia Amanda Canaán-Haden
Rodríguez Abel Mondelo
Yaquis Alejandro Saúl Padrón
Original Assignee
Univ La Habana
Centro De Investig Y Desarrollo De Medicamentos Cidem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ La Habana, Centro De Investig Y Desarrollo De Medicamentos Cidem filed Critical Univ La Habana
Publication of CL2018003114A1 publication Critical patent/CL2018003114A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)

Abstract

LA PRESENTE INVENCIÓN SE RELACIONA CON LA QUÍMICA, LA FARMACÉUTICA Y EN PARTICULAR CON LA OBTENCIÓN DE FORMULACIONES A PARTIR DE DERIVADOS DE COMPUESTOS FENÓLICOS O POLIFENÓLICOS Y A PARTIR DE DERIVADOS DE COMPUESTOS FENÓLICOS O POLIFENÓLICOS COMBINADOS CON SISTEMAS TRICÍCLICOS DEL TIPO BENZODIAZEPINAS FUSIONADAS A DERIVADOS DE 1,4-DIHIDROPIRIDINAS CON ACCIÓN SOBRE EL SISTEMA NERVIOSO CENTRAL Y VASCULAR. ESTAS COMPOSICIONES FARMACÉUTICAS PRESENTAN ACCIÓN GABAÉRGICA, ANTIGLUTAMATÉRGICA, MODULADORA DE LOS CANALES DE CALCIO, MITOPROTECTORA, ANTIOXIDANTE, ANTIINFLAMATORIA, Y ANTIAPOPTOTICA, UTILIZABLES EN EL TRATAMIENTO DE LAS ENFERMEDADES CARDIOVASCULARES, CEREBROVASCULARES, NEURODEGENERATIVAS, NEUROPSIQUIÁTRICAS Y NEUROLÓGICAS.
CL2018003114A 2016-05-04 2018-10-31 Compuesto fenólico y combinación del mismo con una benzodiazepina fusionada a 1,4-dihidropiridina para el tratamiento de afecciones del sistema nervioso central y vascular. CL2018003114A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2016000059A CU24576B1 (es) 2016-05-04 2016-05-04 Compuesto fenólico y combinación del mismo con una benzodiazepina fusionada a 1,4-dihidropiridina para el tratamiento de afecciones del sistema nervioso central y vascular

Publications (1)

Publication Number Publication Date
CL2018003114A1 true CL2018003114A1 (es) 2019-06-14

Family

ID=60202803

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018003114A CL2018003114A1 (es) 2016-05-04 2018-10-31 Compuesto fenólico y combinación del mismo con una benzodiazepina fusionada a 1,4-dihidropiridina para el tratamiento de afecciones del sistema nervioso central y vascular.

Country Status (19)

Country Link
US (1) US10722491B2 (es)
EP (1) EP3453704B1 (es)
JP (1) JP6997995B2 (es)
KR (1) KR102416478B1 (es)
CN (1) CN109476627B (es)
AR (1) AR108370A1 (es)
AU (1) AU2017259749C1 (es)
BR (1) BR112018072579B1 (es)
CA (1) CA3023073C (es)
CL (1) CL2018003114A1 (es)
CO (1) CO2018011927A2 (es)
CU (1) CU24576B1 (es)
EA (1) EA037951B1 (es)
ES (1) ES2878579T3 (es)
MX (1) MX2018013422A (es)
PH (1) PH12018502327A1 (es)
SG (1) SG11201809843SA (es)
WO (1) WO2017190714A1 (es)
ZA (1) ZA201808161B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU20160058A7 (es) 2016-05-04 2017-12-08 Centro De Investigación Y Desarrollo De Medicamentos (Cidem) Organizacion Superior De Desarrollo Emp Derivado de benzodiazepina con actividad sobre el sistema nervioso central y vascular
CA3164091A1 (en) * 2019-12-26 2021-07-15 Centro De Investigacion Y Desarrollo De Medicamentos Cidem Use of a benzodiazepine derivative and method of treatment of traumatic brain injury
CU20190114A7 (es) 2019-12-26 2021-08-06 Centro De Investig Y Desarrollo De Medicamentos Cidem Combinación para simultáneamente incrementar la eficacia analgésica de la morfina y reducir su dependencia física

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5281714A (en) 1990-08-16 1994-01-25 American Home Products Corporation N,N',N'-trisubstituted-5-bisaminomethylene-1,3-dioxane-4,6-dione inhibitors of acyl-CoA: cholesterol-acyl transferase
MX9204939A (es) 1991-09-06 1993-03-01 American Home Prod Inhibidores 5-bis-aminometilen-1,3-dioxan-4,6-diona n,n',n'-trisubstituidas, de la acil coenzima a: colesterol-aciltransferasa.
ES2074770T3 (es) 1992-07-17 1995-09-16 Biogal Gyogyszergyar Procedimiento de preparacion de derivados de 1,3-dioxano-4,6-diona.
JPH11180975A (ja) 1997-10-13 1999-07-06 Chemiprokasei Kaisha Ltd アミノメチレンジオキサン誘導体、その製造方法および用途
EP1737809B1 (en) 2004-02-27 2013-09-18 Amgen, Inc Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
JP2007063444A (ja) * 2005-08-31 2007-03-15 Tdk Corp 錯化合物及びこれを用いた光記録媒体

Also Published As

Publication number Publication date
JP2019516791A (ja) 2019-06-20
JP6997995B2 (ja) 2022-02-04
BR112018072579B1 (pt) 2024-02-20
WO2017190714A1 (es) 2017-11-09
ES2878579T3 (es) 2021-11-19
AR108370A1 (es) 2018-08-15
US10722491B2 (en) 2020-07-28
MX2018013422A (es) 2019-08-16
KR102416478B1 (ko) 2022-07-04
CN109476627A (zh) 2019-03-15
KR20210025138A (ko) 2021-03-09
AU2017259749C1 (en) 2021-12-02
EP3453704B1 (en) 2021-06-16
CU20160059A7 (es) 2017-12-08
US20190133996A1 (en) 2019-05-09
EA201892462A1 (ru) 2019-07-31
SG11201809843SA (en) 2018-12-28
EA037951B1 (ru) 2021-06-11
ZA201808161B (en) 2021-10-27
AU2017259749A1 (en) 2018-12-20
CA3023073C (en) 2022-08-30
CU24576B1 (es) 2022-02-04
BR112018072579A2 (pt) 2019-02-19
EP3453704A1 (en) 2019-03-13
CN109476627B (zh) 2021-06-15
CO2018011927A2 (es) 2019-02-08
CA3023073A1 (en) 2017-11-09
AU2017259749B2 (en) 2021-08-19
PH12018502327A1 (en) 2019-09-02

Similar Documents

Publication Publication Date Title
CL2020000501A1 (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos.
CO2019000386A2 (es) Compuestos heterocíclicos como inmunomoduladores
SV2018005750A (es) Derivados de compuestos de indol sustituidos como inhibidores de la replicacion virica del dengue
MA44498A (fr) Dérivés d'indoline substituée utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue
EA201990495A1 (ru) Биарильные соединения, применимые в качестве иммуномодуляторов
MA48987A (fr) Dérivés d'indoline substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue
EA201891494A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
CL2018002758A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue.
MA48943A (fr) Dérivés d'indoline substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue
CL2017002817A1 (es) Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue
CL2018002729A1 (es) Derivados de indol sustituidos como inhibidores de la replicación vírica del dengue.
CL2018003504A1 (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplasicos.
CL2019003309A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
CL2019002745A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
CL2017000782A1 (es) Derivados de indol mono- o disustituidos como inhibidores de la replicación del virus del dengue
CL2018003114A1 (es) Compuesto fenólico y combinación del mismo con una benzodiazepina fusionada a 1,4-dihidropiridina para el tratamiento de afecciones del sistema nervioso central y vascular.
CL2017000742A1 (es) Indoles mono o disustituidos como inhibidores de la replicación del virus del dengue
AR100691A1 (es) Esteroides neuroactivos, composiciones, y usos de los mismos
CL2017001073A1 (es) 2,4 diamino-quinolia sustituido como nuevos agentes anticancerigenos
MA41341A (fr) Dérivés indole utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue
CL2017002748A1 (es) Formulaciones de emulsión estable de compuestos volatiles encapsulados
AR125457A2 (es) Compuestos inhibidores dobles de magl y faah y composición farmacéutica
CU20190095A7 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
CU20160142A7 (es) Compuesto fenólico y combinación del mismo con una benzodiazepina fusionada a 1,4 dihidropiridina para el tratamiento de afecciones del sistema nervioso central y vascular
EA201990074A1 (ru) Гетероциклические соединения как иммуномодуляторы